Typically after receiving initial chemotherapy for malignant pleural mesothelioma, patients are monitored. In this study, researchers want to see if giving an investigational drug called VS-6063 to patients with pleural mesothelioma who responded well to initial therapy can extend their lives, reduce the risk of recurrence, and improve their quality of life.
Patients will be randomly assigned to receive VS-6063 or a placebo. VS-6063 works by inhibiting an enzyme called FAK that maintains the structure of mesothelioma cells and helps them move through the body. VS-6063 is a tablet that is taken orally (by mouth).